CN110606829B - 一种钯催化合成4-取代喹啉衍生物的方法 - Google Patents
一种钯催化合成4-取代喹啉衍生物的方法 Download PDFInfo
- Publication number
- CN110606829B CN110606829B CN201910919826.0A CN201910919826A CN110606829B CN 110606829 B CN110606829 B CN 110606829B CN 201910919826 A CN201910919826 A CN 201910919826A CN 110606829 B CN110606829 B CN 110606829B
- Authority
- CN
- China
- Prior art keywords
- quinoline
- derivative
- synthesizing
- palladium
- substituted quinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 24
- -1 4-substituted quinoline Chemical class 0.000 title claims abstract description 21
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 16
- 238000006555 catalytic reaction Methods 0.000 title claims abstract description 15
- 229910052763 palladium Inorganic materials 0.000 title claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 14
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 229910000073 phosphorus hydride Inorganic materials 0.000 claims abstract description 6
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 4
- 150000005826 halohydrocarbons Chemical class 0.000 claims abstract description 4
- 239000003446 ligand Substances 0.000 claims abstract description 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 25
- 238000000926 separation method Methods 0.000 claims description 15
- 238000004440 column chromatography Methods 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- QARVLSVVCXYDNA-UHFFFAOYSA-N bromobenzene Chemical compound BrC1=CC=CC=C1 QARVLSVVCXYDNA-UHFFFAOYSA-N 0.000 claims description 10
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 claims description 8
- LUYISICIYVKBTA-UHFFFAOYSA-N 6-methylquinoline Chemical compound N1=CC=CC2=CC(C)=CC=C21 LUYISICIYVKBTA-UHFFFAOYSA-N 0.000 claims description 6
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical compound C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 claims description 6
- 150000008282 halocarbons Chemical class 0.000 claims description 5
- JKDRQYIYVJVOPF-FDGPNNRMSA-L palladium(ii) acetylacetonate Chemical compound [Pd+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O JKDRQYIYVJVOPF-FDGPNNRMSA-L 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 claims description 4
- 239000001282 iso-butane Substances 0.000 claims description 4
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 claims description 4
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 claims description 3
- IVHJSNNMKJWPFW-UHFFFAOYSA-N 7-methoxyquinoline Chemical compound C1=CC=NC2=CC(OC)=CC=C21 IVHJSNNMKJWPFW-UHFFFAOYSA-N 0.000 claims description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 claims description 3
- 229940073608 benzyl chloride Drugs 0.000 claims description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims 2
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 23
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 11
- 239000012295 chemical reaction liquid Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000009286 beneficial effect Effects 0.000 description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- YGUPAQDKOAPZHC-UHFFFAOYSA-N tricyclohexylphosphane Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 YGUPAQDKOAPZHC-UHFFFAOYSA-N 0.000 description 1
- MHNHYTDAOYJUEZ-UHFFFAOYSA-N triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 MHNHYTDAOYJUEZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/584—Recycling of catalysts
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
本发明属于合成化学技术领域,具体为一种钯催化合成4‑取代喹啉衍生物的方法。本发明在乙酰丙酮钯为催化剂,有机膦为配体的条件下,将喹啉或其衍生物、卤代烃和Cs2CO3溶于有机溶剂,在60~80℃下反应5~8小时,分离纯化,即得4‑取代喹啉衍生物。本发明合成工艺简单绿色,具有优良的选择性和较高产率,且具有广泛的底物范围,本发明在药物化学和生物化学等领域具有广泛的应用价值。
Description
技术领域
本发明涉及化学合成技术领域,更具体的说是涉及一种钯催化合成4-取代喹啉衍生物的方法。
背景技术
喹啉是一种重要的化工原料,广泛地用于染料、医药、杀菌剂、除草剂等的工业生产,例如喹啉及其衍生物可用于合成抗疟疾、抗高血压等的药物,一些含喹啉环的衍生物还具有抗肿瘤、抗抑郁、抗菌消炎和抗高血压等生物活性。经过进一步研究发现,喹啉环上如果有取代基可以使其活性大大提高,但是传统合成喹啉衍生物的方法步骤多,产率低,分离困难。
因此如何提供一种利用过渡金属催化法实现喹啉与卤代烃的选择性偶联,从而直接构建4-取代喹啉衍生物具有非常重要的研究意义。
发明内容
有鉴于此,本发明提供了一种钯催化合成4-取代喹啉衍生物的方法,本发明合成工艺简单绿色,具有优良的选择性和较高产率,且具有广泛的底物范围,在药物化学和生物化学等领域具有广泛的应用价值。
为了达到上述目的,本发明采用如下技术方案:
一种钯催化合成4-取代喹啉衍生物的方法,包括以下步骤:
在以乙酰丙酮钯为催化剂,有机膦为配体的条件下,将喹啉或其衍生物、卤代烃和Cs2CO3溶于有机溶剂中,在60~80℃下反应5~8h,分离纯化,即得4-取代喹啉衍生物。
上述技术方案的有益效果是:本发明的化学反应在室温下进行,条件简单、操作方便,并且若温度过低会导致产物产率的下降。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,乙酰丙酮钯、有机膦、喹啉或其衍生物、卤代烃和Cs2CO3的摩尔比为0.05:(0.10~0.12):1.0:(1.1~1.2):1.5。
上述技术方案的有益效果是:上述摩尔比条件下的效率最高,并且不会造成原料的浪费。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,所述分离纯化采用柱层析分离方法,并且淋洗剂是体积比为1:6的二氯甲烷和石油醚。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,所述喹啉或其衍生物为包括但不限于喹啉、6-甲基喹啉、8-甲基喹啉、7-甲氧基喹啉。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,所述卤代烃包括但不限于碘甲烷、溴乙烷、正丙基溴、苄氯、异溴丁烷、溴苯。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,所述有机膦包括但不限于三苯基膦PPh3、三甲基膦PMe3、三环己基膦PCy3。
优选的,在上述一种钯催化合成4-取代喹啉衍生物的方法中,所述有机溶剂为甲苯或四氢呋喃。
上述技术方案的有益效果是:有机溶剂的作用是充分溶解各底物,使反应更加容易进行。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了一种钯催化合成4-取代喹啉衍生物的方法,具有以下优点:
(1)本发明中合成方法简单绿色,使用廉价易得的原料喹啉和卤代烃直接构建4-取代喹啉衍生物;
(2)本发明的反应条件温和,选择性高;
(3)本发明使用廉价易得且性质稳定的乙酰丙酮钯Pd(acac)2为催化剂,绿色经济;
(4)本发明具有很好的底物普适性,从而更好地便于应用。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
在反应管中依次加入喹啉1.0mmol、碘甲烷1.1mmol、催化剂Pd(acac)20.05mmol、PPh30.10mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,60℃下反应8小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为89%。1H NMR(400MHz,CDCl3)δ:8.76(d,J=4.8Hz,1H),8.09(d,J=8.0Hz,1H),7.96~7.95(m,1H),7.70~7.66(m,1H),7.56~7.51(m,1H),7.19(m,1H),2.67(s,3H)。HRMS理论值C10H9N(M)+:143.0735,实际测量值:143.0733。
实施例2:
在反应管中依次加入喹啉1.0mmol、溴乙烷1.2mmol、催化剂Pd(acac)20.05mmol、PMe30.12mmol、Cs2CO31.5mmol,再加入溶剂四氢呋喃3mL,60℃下反应5小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为87%。1H NMR(400MHz,CDCl3)δ:8.81(d,J=4.4Hz,1H),8.12~8.10(m,1H),8.05~8.03(m,1H),7.71~7.67(m,1H),7.57~7.53(m,1H),7.24(d,J=4.4Hz 1H),3.11(q,J=7.5Hz,2H),1.39(t,J=7.5Hz,3H)。HRMS理论值C11H11N(M)+:157.0891,实际测量值:157.0895。
实施例3:
在反应管中依次加入喹啉1.0mmol、正丙基溴1.2mmol、催化剂Pd(acac)20.05mmol、PMe30.10mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,80℃下反应6小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为92%。1HNMR(400MHz,CDCl3)δ:8.80(d,J=4.4Hz 1H),8.11(d,J=8.4Hz,1H),8.05~8.03(m,1H),7.71~7.67(m,1H),7.57~7.53(m,1H),7.23(d,J=4.4Hz,1H),3.05(t,J=7.6Hz,2H),1.85~1.76(m,2H),1.04(t,J=7.4Hz,3H)。HRMS理论值C12H13N(M)+:171.1048,实际测量值:171.1052。
实施例4:
在反应管中依次加入喹啉1.0mmol、苄氯1.1mmol、催化剂Pd(acac)20.05mmol、PCy30.11mmol、Cs2CO31.5mmol,再加入溶剂四氢呋喃3mL,60℃下反应8小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为95%。1H NMR(400MHz,CDCl3)δ:8.86(d,J=4.4Hz,1H),8.18(d,J=8.4Hz,1H),8.08~8.06(m,1H),7.76~7.71(m,1H),7.58~7.54(m,1H),7.37~7.33(m,2H),7.30~7.28(m,1H),7.24~7.23(m,2H),7.17(d,J=4.4Hz,1H),4.48(s,2H)。HRMS理论值C16H13N(M)+:219.1048,实际测量值:219.1046。
实施例5:
在反应管中依次加入喹啉1.0mmol、异溴丁烷1.2mmol、催化剂Pd(acac)20.05mmol、PMe30.12mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,70℃下反应6小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为92%。1H NMR(400MHz,CDCl3)δ:8.80(d,J=4.4Hz,1H),8.12~8.10(m,1H),8.03~8.00(m,1H),7.71~7.66(m,1H),7.56~7.52(m,1H),7.18(d,J=4.4Hz,1H),2.92(d,J=7.2Hz,2H),2.13~2.03(m,1H),0.98(d,J=6.6Hz,6H)。HRMS理论值C13H15N(M)+:185.1204,实际测量值:185.1200。
实施例6:
在反应管中依次加入喹啉1.0mmol、异溴丁烷1.2mmol、催化剂Pd(acac)20.05mmol、PMe30.12mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,70℃下反应6小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为92%。1H NMR(400MHz,CDCl3)δ:8.80(d,J=4.4Hz,1H),8.12~8.10(m,1H),8.03~8.00(m,1H),7.71~7.66(m,1H),7.56~7.52(m,1H),7.18(d,J=4.4Hz,1H),2.92(d,J=7.2Hz,2H),2.13~2.03(m,1H),0.98(d,J=6.6Hz,6H)。HRMS理论值C13H15N(M)+:185.1204,实际测量值:185.1200。
实施例7:
在反应管中依次加入喹啉1.0mmol、溴苯1.1mmol、催化剂Pd(acac)20.05mmol、PPh30.10mmol、Cs2CO31.5mmol,再加入溶剂四氢呋喃3mL,60℃下反应8小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为90%。1H NMR(400MHz,CDCl3)δ:8.93(d,J=4.3Hz,1H),8.18(d,J=8.4Hz,1H),7.91(d,J=8.4Hz,1H),7.70(t,J=7.6Hz,1H),7.52~7.45(m,5H),7.31(d,J=4.3Hz,1H)。HRMS理论值C15H11N(M)+:205.0891,实际测量值:205.0887。
实施例8:
在反应管中依次加入6-甲基喹啉1.0mmol、溴苯1.2mmol、催化剂Pd(acac)20.05mmol、PCy30.12mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,60℃下反应7小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为91%。1H NMR(400MHz,CDCl3)δ:8.86(d,J=4.3Hz,1H),8.08(d,J=8.6Hz,1H),7.66(s,1H),7.57~7.43(m,6H),7.27(d,J=4.3Hz,1H),2.45(s,3H)。HRMS理论值C16H13N(M)+:219.1048,实际测量值:219.1053。
实施例9:
在反应管中依次加入8-甲基喹啉1.0mmol、溴苯1.2mmol、催化剂Pd(acac)20.05mmol、PPh30.10mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,80℃下反应8小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为93%。1H NMR(400MHz,CDCl3)δ:8.97(d,J=4.3Hz,1H),7.76(d,J=8.5Hz,1H),7.58(d,J=6.8Hz,1H),7.54~7.45(m,5H),7.38(t,J=7.7Hz,1H),7.33(d,J=4.3Hz,1H),2.87(s,3H)。HRMS理论值C16H13N(M)+:219.1048,实际测量值:219.1052。
实施例10:
在反应管中依次加入7-甲氧基喹啉1.0mmol、溴乙烷1.2mmol、催化剂Pd(acac)20.05mmol、PPh30.11mmol、Cs2CO31.5mmol,再加入溶剂甲苯3mL,80℃下反应8小时,反应结束后浓缩反应液,柱层析分离得到相应产物,分离产率为96%。1H NMR(400MHz,CDCl3)δ:8.72(d,J=4.5Hz,1H),7.92(d,J=9.2Hz,1H),7.43(d,J=2.6Hz,1H),7.20(dd,J=9.2,2.6Hz,1H),7.12(d,J=4.6Hz,1H),3.95(s,3H),3.06(q,J=7.6Hz,2H),1.37(t,J=7.6Hz,3H)。HRMS理论值C12H13NO(M)+:187.0997,实际测量值:187.0993。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。对于实施例公开的装置而言,由于其与实施例公开的方法相对应,所以描述的比较简单,相关之处参见方法部分说明即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (3)
1.一种钯催化合成4-取代喹啉衍生物的方法,其特征在于,包括以下步骤:
在以乙酰丙酮钯为催化剂,有机膦为配体的条件下,将喹啉或其衍生物、卤代烃和Cs2CO3溶于有机溶剂中,在60~80℃下反应5~8h,分离纯化,即得4-取代喹啉衍生物;
所述喹啉或其衍生物为喹啉、6-甲基喹啉、8-甲基喹啉和7-甲氧基喹啉中的任意一种;
所述卤代烃为碘甲烷、溴乙烷、正丙基溴、苄氯、异溴丁烷和溴苯中的任意一种;
所述有机膦为三苯基膦、三甲基膦和三环己基膦中的任意一种;
所述有机溶剂为甲苯或四氢呋喃。
2.根据权利要求1所述的一种钯催化合成4-取代喹啉衍生物的方法,其特征在于,所述乙酰丙酮钯、所述有机膦、所述喹啉或其衍生物、所述卤代烃和Cs2CO3的摩尔比为0.05:(0.10~0.12):1.0:(1.1~1.2):1.5。
3.根据权利要求1所述的一种钯催化合成4-取代喹啉衍生物的方法,其特征在于,所述分离纯化采用柱层析分离方法,并且淋洗剂是体积比为1:6的二氯甲烷和石油醚。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910919826.0A CN110606829B (zh) | 2019-09-26 | 2019-09-26 | 一种钯催化合成4-取代喹啉衍生物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910919826.0A CN110606829B (zh) | 2019-09-26 | 2019-09-26 | 一种钯催化合成4-取代喹啉衍生物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110606829A CN110606829A (zh) | 2019-12-24 |
CN110606829B true CN110606829B (zh) | 2023-04-28 |
Family
ID=68893662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910919826.0A Expired - Fee Related CN110606829B (zh) | 2019-09-26 | 2019-09-26 | 一种钯催化合成4-取代喹啉衍生物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110606829B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112538045B (zh) * | 2020-11-30 | 2023-06-27 | 上海应用技术大学 | 一种铜催化合成喹啉衍生物的方法 |
CN113372255B (zh) * | 2021-06-28 | 2022-11-15 | 上海应用技术大学 | 一种铜催化合成2-取代吲哚衍生物的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0520695A2 (pt) * | 2005-11-25 | 2009-05-19 | Council Scient Ind Res | processo melhorado para a sìntese de derivados de quinolina |
CN104557696B (zh) * | 2015-01-21 | 2017-08-11 | 重庆工商大学 | 一种合成4‑多氟芳基取代的喹啉酮化合物的方法 |
CN106432072B (zh) * | 2016-09-23 | 2019-09-27 | 大连理工大学 | 一种取代1,2,3,4-四氢喹啉的制备方法 |
CN107739333B (zh) * | 2017-11-14 | 2019-09-27 | 大连理工大学 | 一种绿色的喹啉化合物的制备方法 |
CN109438342A (zh) * | 2018-10-31 | 2019-03-08 | 湘潭大学 | 一种钯催化8-甲基喹啉衍生物与α-酮酸的脱氢偶联反应合成α-酮酸酯的方法 |
-
2019
- 2019-09-26 CN CN201910919826.0A patent/CN110606829B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN110606829A (zh) | 2019-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110606829B (zh) | 一种钯催化合成4-取代喹啉衍生物的方法 | |
CN105001028A (zh) | 一种不对称共轭二炔烃类化合物的合成方法 | |
CN111675662A (zh) | 一种2-三氟甲基取代的喹唑啉酮化合物的制备方法 | |
CN109575014B (zh) | 苯并咪唑并[2,1-a]异喹啉酮化合物及其制备方法 | |
Yamamoto et al. | Asymmetric cross-coupling of potassium 2-butenyltrifluoroborates with aryl and 1-alkenyl bromides catalyzed by a Pd (OAc) 2/Josiphos complex | |
CN112375105B (zh) | 一种n,n-配位的含间位碳硼烷配体的二价镍配合物的应用 | |
CN112480015B (zh) | 一种多组分一锅法合成2-三氟甲基取代的喹唑啉酮的方法 | |
CN113045503B (zh) | 一种2-三氟甲基取代的喹唑啉酮化合物的制备方法以及在合成药物分子中的应用 | |
CN109734662A (zh) | 一种三氟甲基取代二氢异喹啉酮衍生物及其制备方法 | |
CN110804015B (zh) | 一种反式双取代烯烃的制备方法 | |
CN115772157B (zh) | 一种2-烷氧基吲哚化合物的制备方法 | |
CN111004234A (zh) | 一种2-苯基咪唑并[1,2-α]吡啶类化合物的C3位卤化方法 | |
CN115710287A (zh) | 一种无金属催化下环丙烷类化合物开环硼化的反应方法 | |
CN111004164B (zh) | 一种多取代2-芳基吲哚衍生物的制备方法 | |
CN107118196B (zh) | 异香豆素衍生物的制备方法 | |
CN107629049A (zh) | 一种吡啶[2,1‑a]并异吲哚类化合物的合成方法 | |
CN110590679A (zh) | 一种稀土氯化物催化合成5-取代巴比妥酸衍生物的方法 | |
CN112250628B (zh) | 一种钌催化剂催化氢化制备四氢喹啉类化合物的方法 | |
CN110066244A (zh) | 一种利用饱和醛合成手性四氢喹啉的方法 | |
CN109053556A (zh) | 吡啶基桥联-苯基-氨基吡啶类化合物、配合物及其合成与应用 | |
CN109535061A (zh) | 一种3-亚硝基吲哚衍生物及其制备方法 | |
CN104311377A (zh) | 一种联苯类化合物的合成方法 | |
CN110041374A (zh) | 一种钯配合物的制备方法 | |
CN114957097B (zh) | 一种吲哚啉类化合物的制备方法 | |
CN111410656B (zh) | 一种异喹啉酮类衍生物的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20230428 |